You are here

501k Clearance for Ergonomic Pen Needle for Optimal Injection Technique

New Design Offers More Reliable SQ Delivery of Diabetes Meds  

The FDA has given BD 501k clearance for its second-generation Nano pen needle, designed for more reliable subcutaneous injection of diabetes medications.

Proper injection technique is vital for the consistent absorption of insulin, as highlighted in recent updates to the American Diabetes Association’s 2019 Standards of Care

The contoured needle base of BD’s Nano 2nd generation pen needle minimizes the risks from users employing too great a force when injecting by concentrating then distributing pressure closely around the injection site. This helps to ensure a more reliable 4-mm target injection depth compared to similar pen needles. 

In addition to decreasing the intramuscular injection risk, the pen needle’s new design is easier to use, from attachment to disposal, compared to other models.

BD Nano 2nd generation pen needles are expected to be commercially available by the middle of 2019.

Source: BioSpace, January 24, 2019

More Headlines

First and Only Treatment Reduces Depressive Symptoms Within Days
Bone Marrow Cleared of Leukemia in Almost 60% of Patients
Combination of Two Drugs Could Reduce Tumor Growth
Atezolizumab in Combination with Chemotherapy is the Only First-line Cancer Immunotherapy for ES-SCLC
Pre-clinical Trials Showed Drug Inhibits Fibroblast Activity and Collagen Deposition
PARG Inhibitor Exploits Weakness, Kills Cells
Inexpensive, Wearable Therapy Increases Arm Mobility, Reduces Stiffness
California Woman Claimed Asbestos in Talc-Based Powder Caused Her Mesothelioma